US-China Trade Truce Stuns Street: What it means for IT, pharma, and your portfolio

The much-anticipated truce in the US-China tariff war came faster than expected, catching markets worldwide by surprise. While global indices cheered the resolution, the impact on Indian equities may be more nuanced. Zee Business decodes what this rapid breakthrough means for investors at home.

US-China Trade Deal

Both the US and China were entrenched in a protracted tariff war, and most market observers expected negotiations to drag into late 2025 or beyond.

Add Zee Business as a Preferred Source

• The quick resolution is undeniably positive for global trade and economic sentiment, particularly the US markets.

• However, for India, the ceasefire may not be as cheerful. A delayed deal would’ve opened up more trade opportunities for India, especially in sectors where China was facing sanctions.

Sectoral impact: Winners and losers on Dalal Street

Information Technology (IT): Likely to rally

• Hope of easing global tech spending tensions will boost IT stocks.

• Coforge, Persistent, Tech Mahindra among the likely top gainers.

Aviation & Hotels: Tailwinds ahead

• End of geopolitical uncertainty may trigger short covering and fresh buying in travel and hospitality counters.

Banking: Bulls regaining control

• With positive monsoon predictions and geopolitical calm, expect banking stocks to lead the next leg of the rally.

Defence: A breather, not a breakdown

• Minor profit-booking likely after recent run-up due to Indo-Pak tensions.

• Remains a ‘Buy on Dips’ space, according to Zee Busines Research.

Pharma: Big risk alert

• Negative outlook for US-exposed pharma firms.

• Trump is expected to push for a 30–80 per cent cut in drug prices a direct hit to companies like Aurobindo, Dr Reddy’s, and Sun Pharma.

While the trade peace is good news for the world, India’s relative edge in the export and pharma narrative may take a hit. For now, investors are advised to remain nimble and sector-focused.